Skip to main content
SpringerLink
Log in
Book cover

Asbestos and Mesothelioma pp 313–345Cite as

Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma

  • Chapter
  • First Online:

Part of the book series: Current Cancer Research ((CUCR))

Abstract

Despite recent dramatic advances in many solid tumors, malignant mesothelioma remains challenging to treat. Historically, because of the modest number of cases globally and the substantial geographic distribution of patients, large randomized clinical trials were difficult and lengthy to complete, and thus, interest from pharmaceutical companies was limited. Additionally, financial support from various funding agencies is limited for this orphan disease. Consequently, most studies of systemic therapy for mesothelioma were small phase II trials. Despite these limitations, several standards of care were established. This chapter reviews standard cytotoxic chemotherapy treatment for malignant mesothelioma and discusses many novel agents recently and currently under investigation in clinical trials. The roles of surgery, radiation treatment, and combined modality therapy are covered in accompanying chapters. Furthermore, the ongoing development of immunotherapeutic agents is discussed in an accompanying chapter by Hassan and colleagues.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Abdel-Wahab O, Adli M, LaFave LM et al (2012) ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22:180–193

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Abdel-Wahab O, Gao J, Adli M et al (2013) Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 210:2641–2659

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Alberts AS, Falkson G, Van Zyl L (1988) Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna. J Natl Cancer Inst 80:698–700

    Article  CAS  PubMed  Google Scholar 

  • Allen MD, Luong P, Hudson C et al (2014) Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res 74:896–907

    Article  CAS  PubMed  Google Scholar 

  • Ascierto PA, Scala S, Castello G et al (2005) Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 23:7660–7668

    Article  CAS  PubMed  Google Scholar 

  • Avet-Loiseau H, Li JY, Facon T et al (1998) High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 58:5640–5645

    CAS  PubMed  Google Scholar 

  • Baas P, Ardizzoni A, Grossi F et al (2003) The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer 39:353–357

    Article  CAS  PubMed  Google Scholar 

  • Baas P, Boogerd W, Dalesio O et al (2005) Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 48:291–296

    Article  PubMed  Google Scholar 

  • Baas P, van Meerbeeck J, Groen H et al (2000) Caelyx in malignant mesothelioma: a phase II EORTC study. Ann Oncol 11:697–700

    Article  CAS  PubMed  Google Scholar 

  • Bajorin D, Kelsen D, Mintzer DM (1987) Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 71:857–858

    CAS  PubMed  Google Scholar 

  • Barr AR, Gergely F (2007) Aurora-A: the maker and breaker of spindle poles. J Cell Sci 120:2987–2996

    Article  CAS  PubMed  Google Scholar 

  • Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4:314–322

    Article  CAS  PubMed  Google Scholar 

  • Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529

    Article  CAS  PubMed  Google Scholar 

  • Bearz A, Talamini R, Rossoni G et al (2012) Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Res Notes 5:482

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8:235–253

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Belani CP, Adak S, Aisner S et al (2004) Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group. Clin Lung Cancer 6:43–47

    Article  CAS  PubMed  Google Scholar 

  • Bissler JJ, Kingswood JC, Radzikowska E et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381:817–824

    Article  CAS  PubMed  Google Scholar 

  • Blackwell C, Sherk C, Fricko M et al (2016) Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230. Oncotarget 7:39861–39871

    PubMed  PubMed Central  Google Scholar 

  • Bolanos-Garcia VM (2005) Aurora kinases. Int J Biochem Cell Biol 37:1572–1577

    Article  CAS  PubMed  Google Scholar 

  • Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784

    Article  CAS  PubMed  Google Scholar 

  • Bott M, Brevet M, Taylor BS et al (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43:668–672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Boutin C, Irisson M, Guerin JC et al (1987) Phase II trial of vindesine in malignant pleural mesothelioma. Cancer Treat Rep 71:205–206

    CAS  PubMed  Google Scholar 

  • Bueno R, Stawiski EW, Goldstein LD et al (2016) Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48:407–416

    Article  CAS  PubMed  Google Scholar 

  • Buikhuisen WA, Burgers JA, Vincent AD et al (2013) Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 14:543–551

    Article  CAS  PubMed  Google Scholar 

  • Buikhuisen WA, Scharpfenecker M, Griffioen AW et al (2016) A randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomes. J Thorac Oncol 11:758–768

    Article  PubMed  Google Scholar 

  • Bulgar AD, Weeks LD, Miao Y et al (2012) Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair. Cell Death Dis 3:e252

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Busacca S, Chacko AD, Klabatsa A et al (2013) BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma. PLoS One 8:e65489

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Busacca S, Sheaff M, Arthur K et al (2012) BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Pathol 227:200–208

    Article  CAS  PubMed  Google Scholar 

  • Campbell JE, Kuntz KW, Knutson SK et al (2015) EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. ACS Med Chem Lett 6:491–495

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Campbell NP, Kunnavakkam R, Leighl N et al (2012) Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer 78:76–80

    Article  PubMed  PubMed Central  Google Scholar 

  • Cao XX, Mohuiddin I, Ece F et al (2001) Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 25:562–568

    Article  CAS  PubMed  Google Scholar 

  • Carol H, Boehm I, Reynolds CP et al (2011) Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol 68:1291–1304

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Carswell EA, Old LJ, Kassel RL et al (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72:3666–3670

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Carvajal RD, Tse A, Schwartz GK (2006) Aurora kinases: new targets for cancer therapy. Clin Cancer Res 12:6869–6875

    Article  CAS  PubMed  Google Scholar 

  • Castagneto B, Botta M, Aitini E et al (2008) Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 19:370–373

    Article  CAS  PubMed  Google Scholar 

  • Castagneto B, Zai S, Dongiovanni D et al (2005) Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 28:223–226

    Article  CAS  PubMed  Google Scholar 

  • Cedres S, Montero MA, Martinez P et al (2012) Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 77:192–198

    Article  CAS  PubMed  Google Scholar 

  • Ceresoli GL, Castagneto B, Zucali PA et al (2008) Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 99:51–56

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ceresoli GL, Zucali PA, De Vincenzo F et al (2011) Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 72:73–77

    Article  PubMed  Google Scholar 

  • Ceresoli GL, Zucali PA, Favaretto AG et al (2006) Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24:1443–1448

    Article  CAS  PubMed  Google Scholar 

  • Colombo G, Curnis F, De Mori GM et al (2002) Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 277:47891–47897

    Article  CAS  PubMed  Google Scholar 

  • Corti A, Ponzoni M (2004) Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann N Y Acad Sci 1028:104–112

    Article  CAS  PubMed  Google Scholar 

  • Cowan JD, Green S, Lucas J et al (1988) Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study. Investig New Drugs 6:247–248

    Article  CAS  Google Scholar 

  • Creaven PJ, Brenner DE, Cowens JW et al (1989) A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother Pharmacol 23:186–191

    CAS  PubMed  Google Scholar 

  • Crispi S, Fagliarone C, Biroccio A et al (2010) Antiproliferative effect of Aurora kinase targeting in mesothelioma. Lung Cancer 70:271–279

    Article  PubMed  Google Scholar 

  • Curnis F, Arrigoni G, Sacchi A et al (2002) Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 62:867–874

    CAS  PubMed  Google Scholar 

  • Curnis F, Sacchi A, Borgna L et al (2000) Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18:1185–1190

    Article  CAS  PubMed  Google Scholar 

  • Dancey J (2010) mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7:209–219

    Article  CAS  PubMed  Google Scholar 

  • Dar AA, Zaika A, Piazuelo MB et al (2008) Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 112:1688–1698

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Davidson B, Vintman L, Zcharia E et al (2004) Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin Exp Metastasis 21:469–476

    Article  CAS  PubMed  Google Scholar 

  • Dawson MA, Kouzarides T, Huntly BJ (2012) Targeting epigenetic readers in cancer. N Engl J Med 367:647–657

    Article  CAS  PubMed  Google Scholar 

  • Delage B, Fennell DA, Nicholson L et al (2010) Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 126:2762–2772

    CAS  PubMed  Google Scholar 

  • Dey A, Seshasayee D, Noubade R et al (2012) Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 337:1541–1546

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • di Martino E, L’Hote CG, Kennedy W et al (2009) Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene 28:4306–4316

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Dolly SO, Krug LM, Wagner AJ et al (2013) Evaluation of tolerability and anti-tumor activity of Gdc-0980, an oral Pi3k/mtor inhibitor, administered to patients with advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 8:S307–S308

    Google Scholar 

  • Dolly SO, Wagner AJ, Bendell JC et al (2016) Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 22:2874–2884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dowell JE, Dunphy FR, Taub RN et al (2012) A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 77:567–571

    Article  PubMed  Google Scholar 

  • Dubey S, Janne PA, Krug L et al (2010) A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol 5:1655–1661

    Article  PubMed  Google Scholar 

  • Dutt A, Ramos AH, Hammerman PS et al (2011) Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 6:e20351

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dutt A, Salvesen HB, Chen TH et al (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 105:8713–8717

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Duvic M, Talpur R, Ni X et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31–39

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Duvic M, Vu J (2007) Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16:1111–1120

    Article  CAS  PubMed  Google Scholar 

  • Edwards JG, Cox G, Andi A et al (2001) Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 85:863–868

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ellis L, Atadja PW, Johnstone RW (2009) Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 8:1409–1420

    Article  CAS  PubMed  Google Scholar 

  • Epstein Shochet G, Israeli-Shani L, Koslow M et al (2016) Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment. Lung Cancer 96:7–14

    Article  PubMed  Google Scholar 

  • Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411:342–348

    Article  CAS  PubMed  Google Scholar 

  • Falchook G, Kurzrock R, Gouw L et al (2014) Investigational aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Investig New Drugs 32:1181–1187

    Article  CAS  Google Scholar 

  • Falkson G, Hunt M, Borden EC et al (1992) An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Investig New Drugs 10:337–343

    Article  CAS  Google Scholar 

  • Favaretto AG, Aversa SM, Paccagnella A et al (2003) Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 97:2791–2797

    Article  CAS  PubMed  Google Scholar 

  • Fennell DA, Gaudino G, O’Byrne KJ et al (2008) Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 5:136–147

    Article  PubMed  Google Scholar 

  • Fennell DA, McDowell C, Busacca S et al (2012) Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J Thorac Oncol 7:1466–1470

    Article  CAS  PubMed  Google Scholar 

  • Fennell DA, Parmar A, Shamash J et al (2005) Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 23:184–189

    Article  PubMed  Google Scholar 

  • Fine HA, Figg WD, Jaeckle K et al (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708–715

    Article  CAS  PubMed  Google Scholar 

  • Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186

    Article  CAS  PubMed  Google Scholar 

  • Franz DN, Belousova E, Sparagana S et al (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125–132

    Article  CAS  PubMed  Google Scholar 

  • Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13:140–156

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gamm H, Lindemann A, Mertelsmann R et al (1991) Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy. Eur J Cancer 27:856–863

    Article  CAS  PubMed  Google Scholar 

  • Garderet L, Iacobelli S, Moreau P et al (2012) Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 30:2475–2482

    Article  CAS  PubMed  Google Scholar 

  • Garland LL, Chansky K, Wozniak AJ et al (2011) Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol 6:1938–1945

    Article  PubMed  PubMed Central  Google Scholar 

  • Garland LL, Rankin C, Gandara DR et al (2007) Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 25:2406–2413

    Article  CAS  PubMed  Google Scholar 

  • Garrido P, Delgado I, Felip E et al (2015) FP1039/GSK3052230 with chemotherapy in patients with fibroblast growth factor (FGF) pathway deregulated squamous NSCLC or MPM. J Thorac Oncol 10:S403–S403

    Google Scholar 

  • Garrido P, Felip E, Delord JP et al (2014) Multi-arm, nonrandomized, open-label phase Ib study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling. Ann Oncol 25. (abstract)

    Google Scholar 

  • Glazer ES, Piccirillo M, Albino V et al (2010) Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 28:2220–2226

    Article  CAS  PubMed  Google Scholar 

  • Goke F, Bode M, Franzen A et al (2013) Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Mod Pathol 26:1298–1306

    Article  PubMed  CAS  Google Scholar 

  • Gordon GJ, Mani M, Maulik G et al (2008) Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 61:549–558

    Article  CAS  PubMed  Google Scholar 

  • Gordon MS, Rosen LS, Mendelson D et al (2013) A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Investig New Drugs 31:714–723

    Article  CAS  Google Scholar 

  • Gorgun G, Calabrese E, Hideshima T et al (2010) A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115:5202–5213

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Govindan R, Kratzke RA, Herndon JE 2nd et al (2005) Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11:2300–2304

    Article  CAS  PubMed  Google Scholar 

  • Gregorc V, Citterio G, Vitali G et al (2010a) Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer 46:198–206

    Article  CAS  PubMed  Google Scholar 

  • Gregorc V, Zucali PA, Santoro A et al (2010b) Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol 28:2604–2611

    Article  CAS  PubMed  Google Scholar 

  • Grose R, Dickson C (2005) Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16:179–186

    Article  CAS  PubMed  Google Scholar 

  • Guo G, Chmielecki J, Goparaju C et al (2015) Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res 75:264–269

    Article  CAS  PubMed  Google Scholar 

  • Hartman ML, Esposito JM, Yeap BY et al (2010) Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma. J Thorac Cardiovasc Surg 139:1233–1240

    Article  CAS  PubMed  Google Scholar 

  • Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266:1821–1828

    Article  CAS  PubMed  Google Scholar 

  • Hilberg F, Roth GJ, Krssak M et al (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68:4774–4782

    Article  CAS  PubMed  Google Scholar 

  • Hoda MA, Mohamed A, Ghanim B et al (2011) Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. J Thorac Oncol 6:852–863

    Article  PubMed  Google Scholar 

  • Hook KE, Garza SJ, Lira ME et al (2012) An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther 11:710–719

    Article  CAS  PubMed  Google Scholar 

  • Hoque A, Carter J, Xia W et al (2003) Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. Cancer Epidemiol Biomark Prev 12:1518–1522

    CAS  Google Scholar 

  • Huck JJ, Zhang M, McDonald A et al (2010) MLN8054, an inhibitor of aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res 8:373–384

    Article  CAS  PubMed  Google Scholar 

  • Illei PB, Ladanyi M, Rusch VW et al (2003) The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer 99:51–56

    Article  CAS  PubMed  Google Scholar 

  • Itoh N (2007) The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease. Biol Pharm Bull 30:1819–1825

    Article  CAS  PubMed  Google Scholar 

  • Izzo F, Marra P, Beneduce G et al (2004) Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 22:1815–1822

    Article  CAS  PubMed  Google Scholar 

  • Jacobus SJ, Rajkumar SV, Weiss M et al (2016) Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood Cancer J 6:e448

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jahan T, Gu L, Kratzke R et al (2012) Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer 76:393–396

    Article  PubMed  Google Scholar 

  • Janne PA, Wozniak AJ, Belani CP et al (2006) Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol 1:506–512

    Article  PubMed  Google Scholar 

  • Jobgen WS, Fried SK, Fu WJ et al (2006) Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem 17:571–588

    Article  CAS  PubMed  Google Scholar 

  • Kalmadi SR, Rankin C, Kraut MJ et al (2008) Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 60:259–263

    Article  PubMed  Google Scholar 

  • Kao SC, Harvie R, Paturi F et al (2012) The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer 75:248–254

    Article  PubMed  Google Scholar 

  • Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432:316–323

    Article  CAS  PubMed  Google Scholar 

  • Katirtzoglou N, Gkiozos I, Makrilia N et al (2010) Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer 11:30–35

    Article  CAS  PubMed  Google Scholar 

  • Kaufman AJ, Pass HI (2008) Current concepts in malignant pleural mesothelioma. Expert Rev Anticancer Ther 8:293–303

    Article  CAS  PubMed  Google Scholar 

  • Kawabe T (2004) G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3:513–519

    CAS  PubMed  Google Scholar 

  • Kelly WK, O’Connor OA, Krug LM et al (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923–3931

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kimura K, Taguchi T, Urushizaki I et al (1987) Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 20:223–229

    Article  CAS  PubMed  Google Scholar 

  • Kindler HL, Belani CP, Herndon JE 2nd et al (1999) Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer 86:1985–1991

    Article  CAS  PubMed  Google Scholar 

  • Kindler HL, Herndon JE, Zhang C et al (2005) Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 48:423–428

    Article  PubMed  Google Scholar 

  • Kindler HL, Karrison TG, Gandara DR et al (2012) Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30:2509–2515

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kindler HL, Millard F, Herndon JE 2nd et al (2001) Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 31:311–317

    Article  CAS  PubMed  Google Scholar 

  • Knutson SK, Warholic NM, Wigle TJ et al (2013) Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A 110:7922–7927

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Knutson SK, Wigle TJ, Warholic NM et al (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8:890–896

    CAS  PubMed  Google Scholar 

  • Kosty MP, Herndon JE 2nd, Vogelzang NJ et al (2001) High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. Lung Cancer 34:289–295

    Article  CAS  PubMed  Google Scholar 

  • Krug LM, Kindler HL, Calvert H et al (2015) Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 16:447–456

    Article  CAS  PubMed  Google Scholar 

  • Kudo K, Arao T, Tanaka K et al (2011) Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2 + pTyr + peripheral blood leukocytes as a pharmacodynamic biomarker in vivo. Clin Cancer Res 17:1373–1381

    Article  CAS  PubMed  Google Scholar 

  • Kumar S, Flinn I, Richardson PG et al (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119:4375–4382

    Article  CAS  PubMed  Google Scholar 

  • Kumar-Singh S, Segers K, Rodeck U et al (1997a) WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 181:67–74

    Article  CAS  PubMed  Google Scholar 

  • Kumar-Singh S, Vermeulen PB, Weyler J et al (1997b) Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 182:211–216

    Article  CAS  PubMed  Google Scholar 

  • Kumar-Singh S, Weyler J, Martin MJ et al (1999) Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 189:72–78

    Article  CAS  PubMed  Google Scholar 

  • Ladanyi M, Zauderer MG, Krug LM et al (2012) New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res 18:4485–4490

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • LaFave LM, Beguelin W, Koche R et al (2015) Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med 21:1344–1349

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Laurie SA, Gupta A, Chu Q et al (2011) Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group. J Thorac Oncol 6:1950–1954

    Article  PubMed  Google Scholar 

  • Lebwohl D, Anak O, Sahmoud T et al (2013) Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann N Y Acad Sci 1291:14–32

    Article  CAS  PubMed  Google Scholar 

  • Lejeune FJ, Lienard D, Matter M et al (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6:6

    PubMed  Google Scholar 

  • Lerner HJ, Schoenfeld DA, Martin A et al (1983) Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 52:1981–1985

    Article  CAS  PubMed  Google Scholar 

  • Leuzzi V, Alessandri MG, Casarano M et al (2008) Arginine and glycine stimulate creatine synthesis in creatine transporter 1-deficient lymphoblasts. Anal Biochem 375:153–155

    Article  CAS  PubMed  Google Scholar 

  • Li Q, Wang W, Yamada T et al (2011) Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. Am J Pathol 179:1483–1493

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liao RG, Jung J, Tchaicha J et al (2013) Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res 73:5195–5205

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Linder C, Linder S, Munck-Wikland E et al (1998) Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 18:2063–2068

    CAS  PubMed  Google Scholar 

  • Liu L, Gerson SL (2004) Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs 5:623–627

    CAS  PubMed  Google Scholar 

  • Liuzzi M, Talpaert-Borle M (1985) A new approach to the study of the base-excision repair pathway using methoxyamine. J Biol Chem 260:5252–5258

    CAS  PubMed  Google Scholar 

  • Liuzzi M, Weinfeld M, Paterson MC (1987) Selective inhibition by methoxyamine of the apurinic/apyrimidinic endonuclease activity associated with pyrimidine dimer-DNA glycosylases from Micrococcus luteus and bacteriophage T4. Biochemistry 26:3315–3321

    Article  CAS  PubMed  Google Scholar 

  • Locke M, Ghazaly E, Freitas MO et al (2016) Inhibition of the polyamine synthesis pathway is synthetically lethal with loss of argininosuccinate synthase 1. Cell Rep 16:1604–1613

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Loganathan S, Kanteti R, Siddiqui SS et al (2011) Role of protein kinase C beta and vascular endothelial growth factor receptor in malignant pleural mesothelioma: therapeutic implications and the usefulness of Caenorhabditis elegans model organism. J Carcinog 10:4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lopez PG, Felip E, Delord JP et al (2014) Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FCT pathway signaling. J Clin Oncol 32. (abstract)

    Google Scholar 

  • Lopez-Lago MA, Okada T, Murillo MM et al (2009) Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 29:4235–4249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lu YY, Jhanwar SC, Cheng JQ et al (1994) Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. Genes Chromosom Cancer 9:76–80

    Article  CAS  PubMed  Google Scholar 

  • Maksymiuk AW, Marschke RF Jr, Tazelaar HD et al (1998) Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol 21:610–613

    Article  CAS  PubMed  Google Scholar 

  • Manegold C, Symanowski J, Gatzemeier U et al (2005) Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 16:923–927

    Article  CAS  PubMed  Google Scholar 

  • Manfredi MG, Ecsedy JA, Chakravarty A et al (2011) Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 17:7614–7624

    Article  CAS  PubMed  Google Scholar 

  • Marek LA, Hinz TK, von Massenhausen A et al (2014) Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. Mol Cancer Res 12:1460–1469

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Margueron R, Reinberg D (2011) The Polycomb complex PRC2 and its mark in life. Nature 469:343–349

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maris JM, Morton CL, Gorlick R et al (2010) Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 55:26–34

    PubMed  PubMed Central  Google Scholar 

  • Martensson G, Sorenson S (1989) A phase II study of vincristine in malignant mesothelioma--a negative report. Cancer Chemother Pharmacol 24:133–134

    Article  CAS  PubMed  Google Scholar 

  • Marumoto T, Honda S, Hara T et al (2003) Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 278:51786–51795

    Article  CAS  PubMed  Google Scholar 

  • Masood R, Kundra A, Zhu S et al (2003) Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 104:603–610

    Article  CAS  PubMed  Google Scholar 

  • Mathy A, Baas P, Dalesio O et al (2005) Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 50:83–86

    Article  PubMed  Google Scholar 

  • Mazumdar A, Henderson YC, El-Naggar AK et al (2009) Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck 31:625–634

    Article  PubMed  PubMed Central  Google Scholar 

  • Mbidde EK, Harland SJ, Calvert AH et al (1986) Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 18:284–285

    Article  CAS  PubMed  Google Scholar 

  • McCabe MT, Ott HM, Ganji G et al (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492:108–112

    Article  CAS  PubMed  Google Scholar 

  • Mintzer DM, Kelsen D, Frimmer D et al (1985) Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 69:711–712

    CAS  PubMed  Google Scholar 

  • Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51

    Article  CAS  PubMed  Google Scholar 

  • Mittelman A, Puccio C, Gafney E et al (1992) A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion. Investig New Drugs 10:183–190

    Article  CAS  Google Scholar 

  • Moriya M, Yamada T, Tamura M et al (2014) Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma. Oncol Rep 31:1109–1115

    CAS  PubMed  Google Scholar 

  • Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456

    Article  CAS  PubMed  Google Scholar 

  • Neuzil J, Swettenham E, Gellert N (2004) Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochem Biophys Res Commun 314:186–191

    Article  CAS  PubMed  Google Scholar 

  • Nowak AK, Byrne MJ, Williamson R et al (2002) A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87:491–496

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nowak AK, Millward MJ, Creaney J et al (2012) A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol 7:1449–1456

    Article  CAS  PubMed  Google Scholar 

  • O’Brien ME, Gaafar RM, Popat S et al (2013) Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). Eur J Cancer 49:2815–2822

    Article  PubMed  CAS  Google Scholar 

  • Oh Y, Perez-Soler R, Fossella FV et al (2000) Phase II study of intravenous Doxil in malignant pleural mesothelioma. Investig New Drugs 18:243–245

    Article  CAS  Google Scholar 

  • Ohta Y, Shridhar V, Bright RK et al (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81:54–61

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Okada T, Lopez-Lago M, Giancotti FG (2005) Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol 171:361–371

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Orlowski RZ, Nagler A, Sonneveld P et al (2016) Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer 122:2050–2056

    Article  CAS  PubMed  Google Scholar 

  • Orlowski RZ, Nagler A, Sonneveld P et al (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25:3892–3901

    Article  CAS  PubMed  Google Scholar 

  • Otterson GA, Herndon JE 2nd, Watson D et al (2004) Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer 44:251–259

    Article  PubMed  Google Scholar 

  • Ou SH, Moon J, Garland LL et al (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387–391

    Article  CAS  PubMed  Google Scholar 

  • Paik PK, Krug LM (2010) Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol 5:275–279

    Article  PubMed  PubMed Central  Google Scholar 

  • Palumbo A, Bringhen S, Rossi D et al (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28:5101–5109

    Article  CAS  PubMed  Google Scholar 

  • Papa S, Popat S, Shah R et al (2013) Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. J Thorac Oncol 8:783–787

    Article  CAS  PubMed  Google Scholar 

  • Pavel ME, Hainsworth JD, Baudin E et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005–2012

    Article  CAS  PubMed  Google Scholar 

  • Peng CY, Graves PR, Thoma RS et al (1997) Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277:1501–1505

    Article  CAS  PubMed  Google Scholar 

  • Popat S, Mellemgaard A, Fahrbach K et al (2015) Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. Future Oncol 11:409–420

    Article  CAS  PubMed  Google Scholar 

  • Porta C (2006) Adding raltitrexed to cisplatin improves overall survival in people with malignant pleural mesothelioma. Cancer Treat Rev 32:229–233

    Article  CAS  PubMed  Google Scholar 

  • Raghavan D, Gianoutsos P, Bishop J et al (1990) Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 8:151–154

    Article  CAS  PubMed  Google Scholar 

  • Rangel R, Sun Y, Guzman-Rojas L et al (2007) Impaired angiogenesis in aminopeptidase N-null mice. Proc Natl Acad Sci U S A 104:4588–4593

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ranzato E, Grosso S, Patrone M et al (2009) Spreading of mesothelioma cells is rapamycin-sensitive and requires continuing translation. J Cell Biochem 108:867–876

    Article  CAS  PubMed  Google Scholar 

  • Razak AR, Chatten KJ, Hughes AN (2008) Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option. Lung Cancer 60:294–297

    Article  PubMed  Google Scholar 

  • Reck M, Kaiser R, Mellemgaard A et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15:143–155

    Article  CAS  PubMed  Google Scholar 

  • Rosinol L, Oriol A, Teruel AI et al (2012) Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 120:1589–1596

    Article  CAS  PubMed  Google Scholar 

  • Roth GJ, Heckel A, Colbatzky F et al (2009) Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem 52:4466–4480

    Article  CAS  PubMed  Google Scholar 

  • Sahmoud T, Postmus PE, van Pottelsberghe C et al (1997) Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 33:2211–2215

    Article  CAS  PubMed  Google Scholar 

  • Sahtoe DD, van Dijk WJ, Ekkebus R et al (2016) BAP1/ASXL1 recruitment and activation for H2A deubiquitination. Nat Commun 7:10292

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Santoro A, O’Brien ME, Stahel RA et al (2008) Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 3:756–763

    Article  PubMed  Google Scholar 

  • Sartore-Bianchi A, Gasparri F, Galvani A et al (2007) Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 13:5942–5951

    Article  CAS  PubMed  Google Scholar 

  • Scagliotti GV, Gaafar R, Nowak A et al (2016) P2.01: LUME-MeSO: phase II/III study of Nintedanib + Pemetrexed/Cisplatin in patients with malignant pleural mesothelioma: track: SCLC, mesothelioma, thymoma. J Thorac Oncol 11:S216

    Article  PubMed  Google Scholar 

  • Scagliotti GV, Shin DM, Kindler HL et al (2003) Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21:1556–1561

    Article  CAS  PubMed  Google Scholar 

  • Schwartz JE, Scuderi P, Wiggins C et al (1989) A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy. Biotherapy 1:207–214

    Article  CAS  PubMed  Google Scholar 

  • Sells TB, Chau R, Ecsedy JA et al (2015) MLN8054 and Alisertib (MLN8237): discovery of selective oral aurora A inhibitors. ACS Med Chem Lett 6:630–634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shao Y, Lu J, Cheng C et al (2007) Reversible histone acetylation involved in transcriptional regulation of WT1 gene. Acta Biochim Biophys Sin Shanghai 39:931–938

    Article  CAS  PubMed  Google Scholar 

  • Shapiro GI, Tibes R, Gordon MS et al (2011) Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. Clin Cancer Res 17:3431–3442

    Article  CAS  PubMed  Google Scholar 

  • Skubitz KM (2002) Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma. Cancer Investig 20:693–699

    Article  CAS  Google Scholar 

  • Solheim OP, Saeter G, Finnanger AM et al (1992) High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65:956–960

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sonneveld P, Goldschmidt H, Rosinol L et al (2013) Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31:3279–3287

    Article  CAS  PubMed  Google Scholar 

  • Sonneveld P, Schmidt-Wolf IG, van der Holt B et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 30:2946–2955

    Article  CAS  PubMed  Google Scholar 

  • Sorensen PG, Bach F, Bork E et al (1985) Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 69:1431–1432

    CAS  PubMed  Google Scholar 

  • Stebbing J, Powles T, McPherson K et al (2009) The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 63:94–97

    Article  PubMed  Google Scholar 

  • Steele JP, O’Doherty CA, Shamash J et al (2001) Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann Oncol 12:497–499

    Article  CAS  PubMed  Google Scholar 

  • Steele JP, Shamash J, Evans MT et al (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18:3912–3917

    Article  CAS  PubMed  Google Scholar 

  • Strizzi L, Catalano A, Vianale G et al (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193:468–475

    Article  CAS  PubMed  Google Scholar 

  • Sutherlin DP, Bao L, Berry M et al (2011) Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem 54:7579–7587

    Article  CAS  PubMed  Google Scholar 

  • Symanowski J, Vogelzang N, Zawel L et al (2009) A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. J Thorac Oncol 4:149–160

    Article  PubMed  Google Scholar 

  • Synakiewicz A, Stachowicz-Stencel T, Adamkiewicz-Drozynska E (2014) The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials. Expert Opin Investig Drugs 23:1517–1529

    Article  CAS  PubMed  Google Scholar 

  • Syrios J, Nintos G, Georgoulias V (2015) Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 15:875–884

    Article  CAS  PubMed  Google Scholar 

  • Szlosarek PW, Klabatsa A, Pallaska A et al (2006) In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 12:7126–7131

    Article  CAS  PubMed  Google Scholar 

  • Szlosarek PW, Luong P, Phillips MM et al (2013) Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J Clin Oncol 31:e111–e113

    Article  PubMed  Google Scholar 

  • Szlosarek PW, Steele JP, Nolan L et al (2016) Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial. JAMA Oncol. [Epub ahead of print]

    Google Scholar 

  • Takawa M, Masuda K, Kunizaki M et al (2011) Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 102:1298–1305

    Article  CAS  PubMed  Google Scholar 

  • Taylor P, Castagneto B, Dark G et al (2008) Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol 3:764–771

    Article  PubMed  Google Scholar 

  • Thurneysen C, Opitz I, Kurtz S et al (2009) Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 64:140–147

    Article  PubMed  Google Scholar 

  • Tolcher AW, Papadopoulos KP, Patnaik A et al (2016) A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Ann Oncol 27:526–532

    Article  CAS  PubMed  Google Scholar 

  • Tomita M, Mori N (2010) Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro. Cancer Sci 101:1204–1211

    Article  CAS  PubMed  Google Scholar 

  • Tsao AS, Harun N, Lee JJ et al (2014) Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer 15:197–201

    Article  CAS  PubMed  Google Scholar 

  • Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10:116–129

    Article  CAS  PubMed  Google Scholar 

  • Turner N, Pearson A, Sharpe R et al (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70:2085–2094

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • van Haarst JM, Baas P, Manegold C et al (2002) Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86:342–345

    Article  PubMed  PubMed Central  Google Scholar 

  • van Laarhoven HW, Fiedler W, Desar IM et al (2010) Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). Clin Cancer Res 16:1315–1323

    Article  PubMed  CAS  Google Scholar 

  • van Meerbeeck J, Debruyne C, van Zandwijk N et al (1996) Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 74:961–963

    Article  PubMed  PubMed Central  Google Scholar 

  • van Meerbeeck JP, Baas P, Debruyne C et al (1999) A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 85:2577–2582

    Article  PubMed  Google Scholar 

  • van Meerbeeck JP, Baas P, Debruyne C et al (2002) A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. Eur J Cancer 38:779–783

    Article  PubMed  Google Scholar 

  • van Meerbeeck JP, Gaafar R, Manegold C et al (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881–6889

    Article  PubMed  CAS  Google Scholar 

  • Van TT, Hanibuchi M, Goto H et al (2012) SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model. Respirology 17:984–990

    Article  PubMed  Google Scholar 

  • Vandermeers F, Hubert P, Delvenne P et al (2009) Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 15:2818–2828

    Article  CAS  PubMed  Google Scholar 

  • Vermeulen K, Van Bockstaele DR, Berneman ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36:131–149

    Article  CAS  PubMed  Google Scholar 

  • Vogelzang NJ, Goutsou M, Corson JM et al (1990) Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 27:239–242

    Article  CAS  PubMed  Google Scholar 

  • Vogelzang NJ, Herndon JE 2nd, Miller A et al (1999) High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann Oncol 10:597–600

    Article  CAS  PubMed  Google Scholar 

  • Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644

    Article  CAS  PubMed  Google Scholar 

  • Vorobiof DA, Rapoport BL, Chasen MR et al (2002) Malignant pleural mesothelioma: a phase II trial with docetaxel. Ann Oncol 13:412–415

    Article  CAS  PubMed  Google Scholar 

  • Wang F, Li H, Yan XG et al (2015) Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells. Drug Des Develop Ther 9:575–601

    Google Scholar 

  • Weiss J, Sos ML, Seidel D et al (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2:62ra93

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wiedenmann B, Reichardt P, Rath U et al (1989) Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol 115:189–192

    Article  CAS  PubMed  Google Scholar 

  • Wu YM, Su F, Kalyana-Sundaram S et al (2013) Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 3:636–647

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yang TS, Lu SN, Chao Y et al (2010) A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 103:954–960

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yao JC, Lombard-Bohas C, Baudin E et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28:69–76

    Article  CAS  PubMed  Google Scholar 

  • Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5:37–50

    Article  CAS  PubMed  Google Scholar 

  • Zalcman G, Mazieres J, Margery J et al (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387:1405–1414

    Article  CAS  PubMed  Google Scholar 

  • Zauderer MG (2016) A new standard for malignant pleural mesothelioma. Lancet 387:1352–1354

    Article  PubMed  Google Scholar 

  • Zauderer MG, Kass SL, Woo K et al (2014) Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer 84:271–274

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhang XH, Rao M, Loprieato JA et al (2008) Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther 7:1388–1397

    Article  CAS  PubMed  Google Scholar 

  • Zhou S, Liu L, Li H et al (2014) Multipoint targeting of the PI3K/mTOR pathway in mesothelioma. Br J Cancer 110:2479–2488

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zidar BL, Green S, Pierce HI et al (1988) A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Investig New Drugs 6:223–226

    Article  CAS  Google Scholar 

  • Zidar BL, Metch B, Balcerzak SP et al (1992) A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. Cancer 70:2547–2551

    Article  CAS  PubMed  Google Scholar 

  • Zucali PA, Ceresoli GL, Garassino I et al (2008) Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 112:1555–1561

    Article  CAS  PubMed  Google Scholar 

  • Zucali PA, Perrino M, Lorenzi E et al (2014) Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer 84:265–270

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, 10065, USA

    Marjorie G. Zauderer

Authors
  1. Marjorie G. Zauderer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marjorie G. Zauderer .

Editor information

Editors and Affiliations

  1. Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

    Joseph R. Testa

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Zauderer, M.G. (2017). Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma. In: Testa, J. (eds) Asbestos and Mesothelioma. Current Cancer Research. Springer, Cham. https://doi.org/10.1007/978-3-319-53560-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-53560-9_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-53558-6

  • Online ISBN: 978-3-319-53560-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation